

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-46. (cancelled)

47. (new) An aqueous injection preparation of thrombomodulin for being stored/transported in a non-frozen or non-freeze dried liquid form, comprising:

an aqueous injection preparation of thrombomodulin wherein said aqueous injection preparation has a pH value in a range from 5 to 7.0, contains soluble thrombomodulin, contains buffer component(s) having a buffering action in a pH range between 5 and 7.0 and contains surfactant, said preparation has been packed aseptically in a container and is kept aseptically in said container while being stored/transported.

48. (new) The aqueous injection preparation of thrombomodulin according to claim 47, wherein said container filled with aqueous solution is a prefilled syringe preparation and the aqueous solution is in a syringe vessel sealed aseptically by a cap and a stopper.

49. (new) An aqueous injection preparation of thrombomodulin for being stored/transported in a non-frozen or non-freeze dried liquid form, comprising:

an aqueous injection preparation of thrombomodulin wherein said aqueous injection preparation has a pH value in a range from 5 to 7.0, contains soluble thrombomodulin, contains buffer components(s) having a buffering action in a pH range between 5 and 7.0 and contains surfactant, said preparation has been packed aseptically in a container and is kept aseptically in said container while being stored/transported, and wherein said container filled with the aqueous solution is packaged in a sheet or a carton.

50. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein said prefilled syringe preparation is packaged in a sheet or in a carton.

51. (new) The aqueous injection preparation of thrombomodulin according to claim 47, wherein the soluble thrombomodulin is selected from the group consisting of that constituted of the amino acid sequence composed of the amino acid residue from the 19th site to the 516th site of the sequence listing SEQ ID NO:1, that constituted of an amino acid sequence composed of the amino acid residue from the 19th site to the 516th site of the sequence listing SEQ ID NO: 2, that obtained by transfecting a DNA segment coding an amino acid sequence given in the sequence listing SEQ ID NO: 1 to a host cell and that obtained by transfecting a DNA segment coding an amino acid

sequence given in the sequence listing SEQ ID NO: 2 to a host cell.

52. (new) The aqueous injection preparation of thrombomodulin according to claim 47, wherein the pH of the buffer solution is in the range from 5.5 to 6.5.

53. (new) The aqueous injection preparation of thrombomodulin as according to claim 47, wherein said prefilled syringe preparation is for subcutaneous injection or for intramuscular injection.

54. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein the prefilled syringe preparation is characterized in that the aqueous solution of thrombomodulin occupies the syringe container in an amount so that residual gas space therein does not exceed 15% by volume in terms of the proportion of gas space.

55. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein the prefilled syringe preparation is characterized in that the aqueous solution of thrombomodulin occupies the syringe container in such an amount that residual gas space therein does not exceed 10% by volume in terms of the proportion of gas space.

56. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein the prefilled syringe preparation is characterized in that the aqueous solution

of thrombomodulin occupies the syringe container in such an amount that residual gas space therein does not exceed 5% by volume in terms of the proportion of gas space.

57. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein the inner diameter of the syringe container is 8.6 mm or less.

58. (new) The aqueous injection preparation of thrombomodulin according to claim 47, wherein said aqueous solution contains 0.05 to 15 mg/ml of soluble thrombomodulin.

59. (new) The aqueous injection preparation of thrombomodulin according to claim 48, wherein said prefilled syringe preparation has an injection needle.

60. (new) A method for storing/transporting an aqueous injection preparation of thrombomodulin in a non-frozen or non-freeze dried liquid form, comprising:

preparing an aqueous solution having a pH value in a range from 5 to 7.0, wherein said solution contains soluble thrombomodulin and contains buffer component(s) having a buffering action on a pH range between 5 and 7.0, wherein said aqueous solution further comprises a surfactant, and

aseptically packing said aqueous solution in a container wherein said aqueous solution is kept aseptically in the container while being stored/transported.

61. (new) A method for storing/transporting an aqueous injection preparation of thrombomodulin in a non-frozen or non-freeze dried liquid form, comprising:

preparing an aqueous solution having a pH value in a range from 5 to 7.0, wherein said solution contains soluble thrombomodulin and contains buffer component(s) having a buffering action on a pH range between 5 and 7.0, wherein said aqueous solution further comprises a surfactant,

aseptically packing said aqueous solution in a container wherein said aqueous solution is kept aseptically in the container while being stored/transported, and

packaging said container filled with the aqueous solution in a sheet or in a carton.

62. (new) A method for storing/transporting an aqueous injection preparation of thrombomodulin in a non-frozen or non-freeze dried liquid form, comprising:

preparing an aqueous solution having a pH value in a range from 5 to 7.0, wherein said solution contains soluble thrombomodulin and contains buffer component(s) having a buffering action on a pH range between 5 and 7.0, wherein said aqueous solution further comprises a surfactant, and

aseptically packing said aqueous solution in a container wherein said aqueous solution is kept aseptically in the container while being stored/transported and said container

filled with the aqueous solution is a prefilled syringe preparation, wherein the aqueous solution is in a syringe vessel sealed aseptically by a cap and a stopper.

63. (new) The method according to claim 62, further comprising packaging said container filled with the aqueous solution in a sheet or in a carton.

64. (new) The aqueous method according to claim 60, wherein the soluble thrombomodulin is selected from the group consisting of that constituted of the amino acid sequence composed of the amino acid residue from the 19th site to the 516th site of the sequence listing SEQ ID NO:1, that constituted of an amino acid sequence composed of the amino acid residue from the 19th site to the 516th site of the sequence listing SEQ ID NO: 2, that obtained by transfecting a DNA segment coding an amino acid sequence given in the sequence listing SEQ ID NO: 1 to a host cell and that obtained by transfecting a DNA segment coding an amino acid sequence given in the sequence listing SEQ ID NO: 2 to a host cell.

65. (new) The method according to claim 60, wherein the pH of the buffer solution is in the range from 5.5 to 6.5.

66. (new) The method according to claim 62, wherein said prefilled syringe preparation is for subcutaneous injection or for intramuscular injection.

67. (new) The method according to claim 62, wherein the prefilled syringe preparation is characterized in that the aqueous solution of thrombomodulin occupies the syringe container in an amount so that residual gas space therein does not exceed 15% by volume in terms of the proportion of gas space.

68. (new) The method according to claim 62, wherein the prefilled syringe preparation is characterized in that the aqueous solution of thrombomodulin occupies the syringe container in such an amount that residual gas space therein does not exceed 10% by volume in terms of the proportion of gas space.

69. (new) The method according to claim 62, wherein the prefilled syringe preparation is characterized in that the aqueous solution of thrombomodulin occupies the syringe container in such an amount that residual gas space therein does not exceed 5% by volume in terms of the proportion of gas space.

70. (new) The method according to claim 62, wherein the inner diameter of the syringe container is 8.6 mm or less.

71. (new) The method according to claim 60, wherein said aqueous solution contains 0.05 to 15 mg/ml of soluble thrombomodulin.